3.96
전일 마감가:
$4.15
열려 있는:
$4.17
하루 거래량:
533.20K
Relative Volume:
0.74
시가총액:
$131.46M
수익:
-
순이익/손실:
$-86.60M
주가수익비율:
-1.3981
EPS:
-2.8324
순현금흐름:
$-67.37M
1주 성능:
-10.81%
1개월 성능:
+1.28%
6개월 성능:
-18.85%
1년 성능:
-64.61%
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
LXEO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
LXEO
Lexeo Therapeutics Inc
|
3.96 | 239.68M | 0 | -86.60M | -67.37M | -2.8324 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-13 | 개시 | Robert W. Baird | Outperform |
2024-06-06 | 개시 | H.C. Wainwright | Buy |
2023-11-28 | 개시 | Chardan Capital Markets | Buy |
2023-11-28 | 개시 | JP Morgan | Overweight |
2023-11-28 | 개시 | Leerink Partners | Outperform |
2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Is Lexeo Therapeutics Inc. a good long term investmentUnstoppable profit momentum - Autocar Professional
Lexeo Therapeutics Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
What analysts say about Lexeo Therapeutics Inc. stockFree Stock Index Interpretation - Autocar Professional
What drives Lexeo Therapeutics Inc. stock priceUnprecedented growth rates - Autocar Professional
Will Lexeo Therapeutics Inc. stock split in the near futureSafe and Smart Investment Picks - beatles.ru
Lexeo Therapeutics (NASDAQ:LXEO) & Organogenesis (NASDAQ:ORGO) Head to Head Analysis - Defense World
What analysts say about Lexeo Therapeutics Inc. stock outlookFree Investment Portfolio Suggestions - Newser
How high can Lexeo Therapeutics Inc. stock price go in 2025Safe and Smart Investment Picks - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
Why Lexeo Therapeutics Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
How Lexeo Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Lexeo Therapeutics soars 96% following March Fair Value signal By Investing.com - Investing.com South Africa
Lexeo Therapeutics soars 96% following March Fair Value signal - Investing.com
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target - Investing.com Nigeria
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target By Investing.com - Investing.com South Africa
Lexeo Therapeutics stock rises after FDA breakthrough designation By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Secures FDA Breakthrough Therapy Designation for LX2006, Shares Rise 8% in Pre-market Trade. - AInvest
Lexeo Therapeutics announces FDA Breakthrough Therapy Designation for LX2006 - TipRanks
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - Nasdaq
FDA grants breakthrough therapy designation to Lexeo’s FA treatment - Investing.com
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewswire
FDA Breakthrough: Lexeo's Gene Therapy Shows Promise in Fatal Rare Disease Treatment - Stock Titan
FDA grants breakthrough therapy designation to Lexeo’s FA treatment By Investing.com - Investing.com South Africa
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan | ATNFW SEC FilingForm 8-K - Stock Titan
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan - Stock Titan
Lexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.com
Lexeo Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Lexeo Therapeutics, Inc.(NasdaqGM: LXEO) dropped from Russell 2000 Growth Index - MarketScreener
Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases - Pharmafile
Lexeo Therapeutics Partners with PXV Funds, venBio on New Cardiac RNA Therapeutics Venture - MarketScreener
Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares | LXEO Stock News - GuruFocus
Jane Street Group LLC Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Lifted by Wellington Management Group LLP - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 8,378 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Wilson Sonsini Advises Lexeo Therapeutics on $80 Million Private Placement Equity Financing - Wilson Sonsini
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):